Clinical Trial Update: Study of IRX4204 for Treatment of Early Parkinson's Disease [Phase 1]

View source ↗

Summary

Io Therapeutics has completed a Phase 1 study of IRX4204 for early Parkinson's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• IRX4204

Snippet

Sponsor: Io Therapeutics | Conditions: Parkinson's Disease | Phase 1 | Status: COMPLETED